[Amended] Material event report (rights offering)

What happened

Union Korea Pharm Co., Ltd. - Amendment Report

July 8, 2026 1. Disclosure document being amended: Material Event Report (Decision on Rights Offering) 2. Original filing date of the document being amended: May 18, 2026 3. Amended items - 12. Expected listing date of new shares: Reason: Delay due to administrative processing with the Korea Securities Depository; Before: 2026.07.15; After: 2026.07.22

Material Event Report / Exchange Reporting Obligation To the Financial Services Commission / Korea Exchange May 18, 2026 Company name: Union Korea Pharm Co., Ltd. CEO: Jeong Geun-ho Head office: 246 Munmakgongdan-gil, Munmak-eup, Wonju-si, Gangwon-do Phone: 02-489-3611; Website: http://www.ukp.co.kr Preparer: Title Inside Director, Name Im Su-geun, Phone 02-489-3611

Decision on Rights Offering

1. Type and number of new shares: Common shares 51,660,308; Other shares - 2. Par value per share (KRW): 500 3. Total issued shares before the capital increase: Common shares 7,912,828; Other shares - 4. Purpose of fundraising: Facility funds -; Business acquisition funds -; Working capital -; Debt repayment funds -; Funds for acquiring securities of other companies -; Other funds - 5. Capital increase method: Third-party allotment Note (other shares): Basis in articles of incorporation: Article 10 (Preemptive Rights), Paragraph 2, Item 10; content: case where new shares are issued by converting rehabilitation secured claims and rehabilitation claims into equity; other: articles amended with court approval as reflected in the rehabilitation plan.

6. New share issue price: Common shares KRW 500; Other shares - 7. Base share price: Common shares -; Other shares - 7-1. Base share price calculation method: Valuation of a security without a formed market price 7-2. Discount or premium rate (%): - 7-3. Basis for discount/premium rate: -

8. Basis in articles of incorporation for third-party allotment: Article 10 (Preemptive Rights), Paragraph 2, Item 10 - case where new shares are issued by converting rehabilitation secured claims and rehabilitation claims into equity 9. Payment date: May 19, 2026 10. Dividend accrual start date of the new shares: January 1, 2026 11. Expected date of new share certificate delivery: - 12. Expected listing date of new shares: July 22, 2026 13. Whether this is a backdoor listing due to in-kind contribution: No. Whether there is an in-kind contribution: Yes. Whether the in-kind contribution includes shares of an unlisted company: Not applicable. In-kind contribution value: -; as % of total assets for the most recent fiscal year: -. Number of shares to be paid in: -. 14. Whether backdoor-listing requirements are met: Not applicable 15. Board resolution date: May 13, 2026; outside directors' attendance: attended -, absent -; auditor (audit committee member) attendance: - 16. Whether subject to filing a securities registration statement: No 17. Reason for exemption: Under Article 277 of the Debtor Rehabilitation and Bankruptcy Act, when a debtor or new company that is a stock corporation issues shares or bonds, Article 119 (Registration of Offer or Sale) of the Financial Investment Services and Capital Markets Act does not apply. 18. Whether within a short-sale subscription-prohibition period: No; start -; end - 19. Whether subject to Fair Trade Commission reporting: Not applicable

20. Other matters for investors' reference 1) Pursuant to the Debtor Rehabilitation and Bankruptcy Act, the Company received rehabilitation plan approval from the Seoul Bankruptcy Court on May 12, 2026; board and shareholders' meeting resolutions are replaced by court approval. 2) Per the approved plan, the Company will sequentially carry out a debt-to-equity conversion (effective May 19, 2026), a capital reduction/consolidation (effective May 27, 2026), and a third-party allotment rights offering (effective May 28, 2026). 3) The "9. Payment date" is the effective date of the debt-to-equity conversion of rehabilitation claims; there is no new payment of subscription money. 4) The "12. Expected listing date" may change per the rehabilitation court's decisions and administrative procedures, and will be re-disclosed if changed. 5) The "13. In-kind contribution" concerns repayment of the Company's debts (rehabilitation secured claims and rehabilitation claims) through new share issuance. 6) The "15. Board resolution date" is the date the decision approving the rehabilitation plan was received from the Seoul Bankruptcy Court; the purpose of the new share issuance is repayment via debt-to-equity conversion of a portion of the rehabilitation claims (as stated in the filing, this item is numbered "6)" twice). 7) The Company's largest shareholder is expected to change as a result of this debt-to-equity conversion. 8) The execution procedure will proceed per the approved rehabilitation plan (the administrator files for court approval of the shareholders' rights change/debt-to-equity conversion, then repays claims and issues new shares), and may change depending on processing by relevant authorities. 9) Fractional shares of less than one share arising from the conversion will be retired without consideration by the administrator with the rehabilitation court's approval; the number of issued shares and capital stock after the share consolidation may change due to such fractional differences. 10) The effective date may change depending on administrative processing progress. 11) If undetermined rehabilitation claims become fixed through an investigation/determination trial, objection suit, or other litigation, new shares will be issued with court approval.

Additional information for a listed company issuing a security without a formed market price (Unit: KRW, %): Trading suspension date October 11, 2024; last closing price before suspension (A): KRW 2,725; base-price evaluation method -; change ratio (B-A)/A*100 -; external valuation performed -; evaluation method -; evaluation amount (B) -; evaluator name -.

[Basis and purpose of third-party allotment]: Articles of incorporation basis: Article 10 (Preemptive Rights), Paragraph 2, Item 10 - conversion of rehabilitation secured claims/claims into equity. Purpose: debt repayment through debt-to-equity conversion.

[Specific use of funds raised through third-party allotment] (working capital/other funds, KRW): fund use/detail/planned amount by year all -; total other funds -. Note 1: Debt repayment through debt-to-equity conversion.

[Selection background, transaction details, and allotment details by third-party allottee] (top 5 by shares allotted; relationship and transaction details not stated for any): Park Gwang-seok: selection background debt-to-equity conversion of rehabilitation claims; shares allotted 9,455,845 Kookmin Bank Co., Ltd.: selection background debt-to-equity conversion of rehabilitation claims; shares allotted 4,042,264 Korea Asset Management Corporation: selection background debt-to-equity conversion of rehabilitation claims; shares allotted 2,419,598 Mark420 Co., Ltd.: selection background debt-to-equity conversion of rehabilitation claims; shares allotted 2,160,064 Yeom Ho: selection background debt-to-equity conversion of rehabilitation claims; shares allotted 1,394,410 Note: Not all allottees are listed; only the top 5 by shares allotted are stated.